Гендерные особенности желудочково-предсердного ремоделирования при рецидивирующей фибрилляции предсердий у больных ишемической болезнью сердца с артериальной гипертонией

фибрилляция предсердий, ремоделирование сердца, гендерные различия, ишемическая болезнь сердца, артериальная гипертония, atrial fibrillation, cardiac remodeling, gender differences, ischemic heart disease, hypertension

1. Marzec L., Wang J., Shah N. et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. J. Am Coll Cardiol 2017; 69 (20): 2475-2484.

2. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893-2962.

3. Сулимов В.А., Голицын С.П., Панченко Е.П., и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал 2013; 4 (прил. 3): 1-100

4. Andersson T., Magnuson A., Bryngelsson I. et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013; 34: 1061-1067.

5. Pandey A., Kim S., Moore C. et al. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail 2017; 5 (1): 44-52.

6. Elsen A., Ruff C., Braunwald E. et al. Sudden Cardiac Death in Patients With Atrial Fibrillation: Inssights From the ENGAGE AF-TIMI 48. J. Am Heart Assoc 2016; 5 (7).pii: e003735.

7. Miller C., Grandi S., Shimony A. et al. Meta-analysisi of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J. Cardiol 2012; 110 (3): 453-460.

8. Benjamin E., Wolf P., DAgostino R. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98 (10): 946-952.

9. Emdin C., Wong C., Hsiao A. et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016; 532: h7013.

10. Dagres N., Nieuwlaat R., Vardas P. et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey onAtrial Fibrillation. J. Am Coll Cardiol 2007; 49 (5): 572-577.

11. Rienstra M., Van Veldhuisen D., Hagens V. et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J. Am Coll Cardiol 2005; 46 (7): 1298-1306.

12. LeWinter M., Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it's not one thing it's another. Circ Heart Fail 2013; 6 (6): 1112-1115.

13. Meluzin J., Starek Z., Kulik T. et al. Prevalence and Predictors of Early Heart Failure with Preserved Ejection Fraction in Patients with Paroxysmal Atrial Fibrillation. J. Card Fail 2017; pii: S1071-9164 (17) 30095-7.

14. Williams B., Lacy P., Thom S. et al. for the CAFE and ASCOT investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006; 113: 1213-1225.

15. London G., Asmar R., O'Rourke M. et al. Mechanism (s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J. Am Coll Cardiol 2004; 43: 92-99.

16. Boutouyrie P., Achouba A., Trunet P., Laurent S. for the EXPLOR Trialist Group. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study. Hypertension 2010; 55: 1314-1322.

17. Goupil R., Dupuis D., Troyanov S. et al. Heart rate dependent and independent effects of beta-blockers on central hemodynamic parameters. J. Hypertens 2016; 34 (8): 1535-1543.

18. Sardana M., Syed A., Hashmath Z. et al. Beta-blocker use is associated with impaired left atrial function in hypertension. J. Am Heart Assoc 2017; 6 (2): e005163.

19. Zimmermann A., Bossard M., Aeschbacher S. et al. Time course of left atrial and ventricular function after electrical cardioversion in patients with atrial fibrillation by 3-D echocardiography. Eur Heart J. 2013; 34 (suppl 1): P1103 - P1103.

20. Kasner M., Sinning D., Burkhoff D. et al. Diastolic pressure-vol-ume quotient (DPVQ) as a novel echocardiographic index for estimation of LV stiffness in HFpEF. Clin Res Cardiol 2015; 104 (11): 955-963.

21. Casaclang-Verzosa G., Gersh B., Tsang T. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J. Am Coll Cardiol 2008; 51 (1): 1-11.

22. Gupta S., Matulevicius S., Ayers C. et al. Left atrial structure and function and clinical outcomes in the general population. Eur Heart J. 2013; 34 (4): 278-285.

23. Hsu P., Lee W., Chu C. et al. Prognostic role of left atrial strain and its combination index with transmitral E-wave velocity in patients with atrial fibrillation. Sci Rep 2016; 6: 17318.

24. Pellicori P., Zhang J., Lukaschuk E. et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J. 2015; 36 (12): 733-742.

25. Zile M., Gottdiener J., Hetzel S. et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124 (23): 2491-2501.

26. Melenovsky V., Hwang S., Redfield M. et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Cicr Heart Fail 2015; 8 (2): 295-303.

27. Santhanakrishnan R., Wang N., Larson M. et al. Atrial Fibrillation Begets heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation 2016; 133 (5): 484-492.

28. Scantlebury D.C., Borlaug B.A. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol 2011; 26: 562-568.

29. Proietti M., Raparelli V., Basili S. et al. Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. Int J. Cardiol 2016; 207: 258-263.

30. Alasady M., Abhayaratna W., Leong D. et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm 2011; 8 (7): 955-960.

31. Lokshyn S., Mewis C., Kuhlkamp V. Atrial fibrillation in coronary artery disease. Int J. Cardiol 2000; 72 (2): 133-136.

32. Tanabe Y., Kawamura Y., Sakamoto N. et al. Blood pressure control and the reduction of left atrial overload is essential for controlling atrial fibrillation. Int Heart J. 2009; 50 (4): 445-456.

33. Cameli M., Mandoli G., Mondillo S. Left atrium: the last bulwark before overt heart failure. Heart Fail Rev 2017; 22 (1): 123-131.

34. Matsuda M., Matsuda Y. Mechanism of left atrial enlargement related to ventricular diastolic impairment in hypertension. Clin Cardiol 1996; 19 (12): 954-959.

35. Yu H., Lee J., Kim T. et al. Advanced Left Atrial Remodeling and Appendage Contractile Dysfunction in Women Than in Men Among the Patients With Atrial Fibrillation: Potential Mechanism of Stroke. J. Am Heart Assoc 2016; 5 (7): e003361.

36. Okura H., Takada Y., Yamabe A. et al. Age- and gender-specific changes in the left ventricular relaxation: a Doppler echocardio-graphic study in healthy individuals. Circ Cardiovasc Imag 2009; 2 (1): 41-46.

37. Voors A., Terpstra W., Smit A. et al. Gender-related differences in left ventricular structural and functional responses to hypertension. J. Hum Hypertens 2005; 19 (11): 915-917.

38. Ferreira R., Worthington A., Huang C. et al. Sex differences in the prevalence of diastolic dysfunction in cardiac surgical patients. J. Card Surg 2015; 30 (3): 238-245.

39. Coutinho T., Pellikka P., Bailey K. et al. Sex Differences in the Associations of Hemodynamic Load With Left Ventricular Hypertrophy and Concentric Remodeling. Am J. Hypertens 2016; 29 (1): 73-80.

40. Mizuguchi Y., Oishi Y., Miyoshi H. et al. Concentric left ventricular hypertrophy brings deterioration of systolic longitudinal, circumferential, and radial myocardial deformation in hypertensive patients with preserved left ventricular pump function. J. Cardiol 2010; 55 (1) 23-33.

41. Masugata H., Senda S., Inukai M. et al. Differences in left ventricular diastolic dysfunction between eccentric and concentric left ventricular hypertrophy in hypertensive patients with preserved systolic function. J. Int Med Res 2011; 39 (3): 772-779.

42. Li Z., Wang Z., Yin Z. et al. Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget 2017. doi: 10.18632/oncotarget.16342.

43. Hashimoto J., Imai Y., O'Rourke M.F. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J. Hypertens 2007; 20 (4): 378-384.

44. Kaji Y., Miyoshi T., Doi M. et al. Augmentation index is associated with B-type natriuretic peptide in patients with paroxysmal atrial fibrillation. Hypertens Res 2009; 32 (7): 611-616.

45. Chirinos J., Segers P., Rietzschel E. et al. Early and late systolic wall stress differentially relate to myocardial contraction and relaxation in middle-aged adults: the Asklepios study. Hypertension 2013; 61: 296-303.

46. Shim C., Park S., Choi D. et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J. Am Coll Cardiol 2011; 57 (10): 1226-1233.

47. Higashi H., Okayama H., Saito M. et al. Relationship between augmentation index and left ventricular diastolic function in healthy women and men. Am J. Hypertens 2013; 26 (11): 1280-1286.

48. Wilkinson I., MacCallum H., Flint L. et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J. Physiol 2000; 525Pr1: 263-270.

49. Hammoudi N., Achkar M., Laveau F. et al. Left atrial volume predicts abnormal exercise left ventricular filling pressure. Eur J. Heart Fail 2014; 16 (10): 1089-1095.

50. Sanfilippo A., Abascal V., Sheehan M. et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990; 82 (3): 792-797.

51. Hoshida S., Shinoda Y., Ikeoka K. et al. Age- and sex-related differences in diastolic function and cardiac dimensions in a hypertensive population. ESC Heart Fail 2016; 3 (4): 270-277.

52. Colin P., Ghaleh B., Hittinger L. et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J. Physiol Heart Circ Physiol 2002; 282 (2): H672-9.

53. Komajda M., Isnard R., Cohen-Solal A. et al.; prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J. Heart Fail 2017 Apr 30. doi: 10.1002/ejhf.876.

54. Lancellotti P., Henri C. The left atrium: an old 'barometer' which can reveal great secrets. Eur J. Heart Fail 2014; 16 (10): 1047-1048.